Metformin plus targeted lung cancer drugs for EGFR-mutated cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 3 study tests whether adding metformin to standard targeted medicines (tyrosine kinase inhibitors) helps people with EGFR-mutated non-small cell lung cancer. It’s meant for people who haven’t already had EGFR-targeted treatment and who have healthy enough labs and organs to safely take the study medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have non-small cell lung cancer that is stage IIIB to IV and confirmed by biopsy/pathology
- Have EGFR mutation that makes the cancer sensitive to EGFR-targeted drugs (a “sensitizing” mutation)
- Have measurable cancer on scans (so doctors can track changes during treatment)
- Be age 18 or older, with an OK activity level (ECOG 0–2) and at least 12 weeks of expected lifespan
- Not have taken any EGFR-targeted medicine before (chemotherapy before is allowed if stopped at least 6 months ago)
- Be able to take pills, and have required blood tests and organ function (kidney, liver, and blood counts) within study limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a combination of two drugs—nintedanib and an EGFR inhibitor—for people with EGFR-mutated non-small cell lung cancer whose cancer has stopped responding to their first EGFR inhibitor treatment. The goal is to see if adding nintedanib can help control the cancer again.
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
This trial studies an oral (by mouth) EGFR-blocking medicine (DZD9008) in people with advanced lung cancer that has EGFR mutations. It’s for cancers that have grown despite standard treatment or couldn’t be tolerated, and aims to control the cancer while keeping side effects manageable.
This Phase 2 trial tests whether adding OBI-833/OBI-821 to the standard targeted pill erlotinib works better for some people with EGFR-mutated lung cancer. It may help shrink tumors that already started responding to erlotinib.
This trial tests a combination of pembrolizumab (an immunotherapy) and chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a specific EGFR mutation (exon 21) and a PD-L1 score of 1% or higher. It aims to see if this combination can help shrink tumors and improve outcomes for those who have not yet received any anticancer treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.